Celeste Richardson

Led the strategic, operational, and scientific development of innovative CAR T cell and engineered TCR T cell therapies spanning early discovery to IND preparation, including the management of a 22-person scientific team and cross-functional internal and external partnerships.

Built and led Research team, comprising 15 in vitro and in vivo scientists, to develop transposon engineering technology for allogeneic CAR-NK cell therapies.

Led regulation technology POC, product concept ideation, and development candidate nomination for CAR-T and TIL cell therapies. Built and managed team of 18 in vitro and in vivo scientists.

Immuno-Oncology and Cell Therapy Leader of global project teams in T-cell therapies. Manager of scientific team and strategic direction in chimeric antigen receptor T-cell (CART) therapy to build an innovative pipeline encompassing novel targets and gene editing technologies. Leader of external collaborations in gene editing and gene therapy.

Cancer Immunotherapy and Cell Therapeutics: Leader of global project teams in chimeric antigen receptor T-cell (CART) based therapeutics for Oncology. Scientific and strategic manager of projects from target identification to IND submission. Leader of external collaborations in genome editing and gene therapy.

Oncology antibody therapeutics: Lead global drug discovery teams for antibody therapeutics and antibody drug conjugates. Managed projects with internal and external collaborators. Progressed lead selection activities to scientific and strategic decision points.

Oncology targets and biomarkers discovery: Led scientific team in the discovery of novel targets and small molecule combinations to broaden the Oncology pipeline.